Results 151 to 160 of about 44,151 (306)
Cochrane Database of Systematic Reviews, 2018 BACKGROUND Non-selective beta-blockers are recommended for the prevention of bleeding in people with cirrhosis, portal hypertension and gastroesophageal varices. Carvedilol is a non-selective beta-blocker with additional intrinsic alpha1-blocking effects,
A. Zacharias +5 more
semanticscholar +1 more source
On the Proportional Principal Stratum Hazards Model [PDF]
arXivIn clinical trials involving both mortality and morbidity, an active treatment can influence the observed risk of the first non-fatal event either directly, through its effect on the underlying non-fatal event process, or indirectly, through its effect on the death process, or both.
arxiv
Cardiotoxicity and cancer therapy [PDF]
, 2014 A fundamental concept of treatment is to do no harm. However, with cancer treatment this is not always possible. Chemotherapy is associated with cardiovascular (CV) complications.1,2 This risk is even greater in the elderly patients and patients with ...
Kolovou, G +2 more
core
Carvedilol Protects against Doxorubicin-Induced Mitochondrial Cardiomyopathy [PDF]
, 2002 Several cytopathic mechanisms have been suggested to mediate the dose-limiting cumulative and irreversible cardiomyopathy caused by doxorubicin. Recent evidence indicates that oxidative stress and mitochondrial dysfunction are key factors in the ...
Froberg, M. K. +4 more
core +1 more source
Carvedilol for prevention of variceal bleeding: a systematic review and meta-analysis
Annals of gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology, 2019 Background Beta-blockers are used for prophylaxis of variceal bleeding. Our aim was to assess the efficacy and safety of carvedilol for primary or secondary prevention of variceal bleeding in patients with cirrhosis.
K. Malandris +8 more
semanticscholar +1 more source
Carvedilol in the treatment of portal hypertension
Saudi Journal of Gastroenterology, 2011 Variceal bleeding is a major event in the natural history of end-stage liver disease with a subsequent high mortality rate. Non-selective β-blockers are currently the drugs of choice for preventing first variceal bleeding. Endoscopic rubber band ligation of high risk varices features as a first line option if cirrhotic patients cannot tolerate β ...
openaire +4 more sources
Severe carvedilol toxicity without overdose – caution in cirrhosis
Clinical Hypertension, 2017 Background Carvedilol is used in the management of hypertension, ischemic heart disease, heart failure and most recently, portal hypertension. It has been associated with improved outcomes regarding variceal bleeding, hepatic decompensation and death ...
Satish Maharaj +5 more
doaj +1 more source
Carvedilol and bisoprolol effectiveness in patients with myocardial infarction and heart failure
Кардиоваскулярная терапия и профилактика, 2008 Aim. To assess carvedilol and bisoprolol effects on clinical symptoms, hemodynamics and morpho-functional heart characteristics in patients with myocardial infarction (MI) and chronic heart failure (CHF).Material and methods.
A. I. Chesnikova +3 more
doaj
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. [PDF]
, 2016 AimsIn this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril ...
Claggett, Brian +12 more
core +1 more source
Annals of Hepatology, 2014 Background. Carvedilol appears to be more effective than propranolol in the treatment of portal hypertension in cirrhotic patients.Aim. To compare the effects of carvedilol vs.
Nancy Aguilar-Olivos +6 more
doaj